Molecular diagnostics company Celera Corp. said Friday the Food and Drug Administration approved new system software used for HIV monitoring and treatment.
The new software for the ViroSeq HIV-1 Genotyping system is designed to detect mutations in the HIV-1 genome that could confer drug resistance.
"The ViroSeq HIV-1 Genotyping System has become a standardized tool for physicians seeking the best course of drug treatment for HIV-1 infected individuals through monitoring of viral resistance," said Michael Zoccoli, general manager of Celera's products business, in a statement. "To ensure better management of HIV-1 infected patients, it is critical that we update our ViroSeq drug resistance algorithm to keep pace with new therapeutic interventions that optimize treatment of this life threatening disease."
The system is made by Celera and distributed by North Chicago, Ill.-based Abbott Laboratories.
Shares of Celera rose 12 cents to $12.93 while shares of Abbott rose 22 cents to $57.72 in morning trading.
Terms & Conditions
RSS Headlines
Fool UK